{
  "type": "article",
  "title": "Sanofi India Announces Rs 377 Dividend Per Share As Sharekhan Projects Rs 6,200 Price Target",
  "summary": "Sanofi India has declared a combined dividend payout of 3770% totaling Rs 377 per share. Brokerage firm Sharekhan recommends buying the stock at Rs 5,750 with a target of Rs 6,200.",
  "content": "Multinational pharmaceutical manufacturer Sanofi India has declared an exceptionally large cash distribution for its equity holders. The company has approved a massive 3770% cumulative dividend payout, translating to Rs 377 per equity share based on a nominal face value of Rs 10. The move delivers an immediate cash return opportunity for market participants evaluating defensive healthcare counters.\n\nBreakdown of the Payout and Critical Ex-Dividend Timeline\nThe total payout declared by Sanofi India is split into two distinct dividend categories. The board declared a final dividend of 1940%, alongside an additional special dividend of 1830%. Combining both allocations brings the total corporate action to 3770%, yielding Rs 377 for every share carrying a face value of Rs 10.\n\nMarket participants tracking this income distribution must take note of the calendar schedule. Sanofi India equity shares will trade ex-dividend on April 28, 2023. Investors seeking eligibility for this payment must acquire the shares prior to this cutoff session. Furthermore, capital market tax regulations apply directly to these distributions. Dividend earnings are taxable in the hands of equity holders according to individual income slabs, making tax planning essential for participants positioned in the highest tax bracket.\n\nSharekhan Brokerage View and Price Band Metrics\nDomestic brokerage institution Sharekhan has issued a buy recommendation on Sanofi India equity, establishing a price target of Rs 6200. This projected target offers a notable premium above the prevailing market price of Rs 5750, indicating potential upside room for the stock.\n\nEntering the counter at the prevailing valuation alongside the upcoming payout structure effectively trims the net acquisition cost by Rs 377 per share. Reviewing the trading performance over the past year shows that Sanofi shares recorded a 52-week peak of Rs 7938, alongside a 52-week trough of Rs 5240. The current pricing places the counter comfortably above its yearly base while trading at a discount to its prior high.\n\nGlobal Ownership Foundation and Therapy Portfolio\nSanofi India operates as the domestic arm of one of the premier global healthcare corporations. Global entity Sanofi, in conjunction with its wholly owned subsidiary Hoechst GmbH, represents the primary controlling group of Sanofi India Limited, collectively controlling a 60.4% ownership stake in the enterprise's paid-up equity capital.\n\nThe drug manufacturer maintains a specialized footprint across multiple therapeutic categories. Its portfolio spans vital treatments in diabetes care, cardiology, thrombosis, central nervous system disorders, and anti-histamine formulas. Pharmaceuticals produced across its facilities supply domestic supply channels throughout India and are exported to a wide spectrum of developed and emerging international markets. Supported by robust operational performance across recent years, the company remains positioned to sustain strong dividend yields over the operating cycle.\n\nWhat this means for you\nSanofi India shareholders and market participants holding the stock ahead of April 28, 2023, stand to receive a direct cash dividend of Rs 377 per share.\n\n• Dividend Payout Value: Eligible equity holders will receive a gross distribution of Rs 377 on every share with a face value of Rs 10. The approved funds will be directly credited to the investor's linked bank account.\n• Purchase Deadline: The stock turns ex-dividend on April 28, 2023. Investors looking to capture this income stream must conclude their purchases before the ex-date.\n• Taxation Rules: All dividend receipts are treated as taxable income directly in the hands of the recipient. Investors falling into higher income tax brackets will incur obligations based on their applicable marginal rates.\n• Net Acquisition Impact: Receiving Rs 377 against the current trading price of Rs 5,750 effectively softens the entry cost. Capturing the projected Sharekhan target of Rs 6,200 would combine direct dividend yield with capital appreciation.\n\nWhy this happened\nSanofi India announced a combined regular and special dividend distribution on the back of resilient operational earnings and comfortable liquidity reserves.\n\n• Robust Operational Trajectory: The company maintained strong financial execution across its core domestic and export drug portfolios over recent operating cycles. This underlying profitability supported the declaration of a 1940% final dividend component.\n• Special Dividend Distribution: In addition to the base dividend, the board approved an 1830% special payout. This supplemental corporate distribution reflects surplus capital reserves returned directly to the investor base.\n• Multinational Parent Strategy: The controlling group consisting of Sanofi and Hoechst GmbH holds a 60.4% equity stake in the company. Multinational pharmaceutical subsidiaries routinely use dividend mechanisms to deliver attractive capital yields from cash flows.\n\nQuestions & Answers\n\n1. What is the total dividend declared by Sanofi India?\nThe company declared a total dividend of 3770%, which amounts to Rs 377 per share on a face value of Rs 10.\n\n2. What is the split between the final and special dividend?\nThe distribution comprises a final dividend of 1940% and a special dividend of 1830%.\n\n3. What is the cutoff ex-dividend date to receive this payout?\nThe shares will trade ex-dividend on April 28, 2023, requiring investors to purchase the stock prior to that date.\n\n4. What price target has Sharekhan established for the stock?\nSharekhan issued a buy rating on Sanofi India with a price target of Rs 6,200.\n\n5. What are the 52-week high and low figures for Sanofi India shares?\nThe stock recorded a 52-week high of Rs 7,938 and a 52-week low of Rs 5,240.\n\n6. How much stake do the promoter entities hold in Sanofi India?\nSanofi and its wholly owned subsidiary Hoechst GmbH together hold a 60.4% stake in Sanofi India Limited.",
  "url": "https://trendkia.com/en/money/sanofi-india-ne-ghoshita-kiya-377-prati-sheyara-ka-bhari-dividenda-sharekhan-ne-diya-6-200-ka-tarageta-53378",
  "category": "Money",
  "publishedAt": "2026-10-30",
  "tags": [
    "Sanofi India",
    "Dividend",
    "Sharekhan",
    "Stock Market",
    "Pharma Stocks",
    "Earnings"
  ],
  "language": "en",
  "site": "TrendKia",
  "whatItMeansForYou": "Sanofi India shareholders and market participants holding the stock ahead of April 28, 2023, stand to receive a direct cash dividend of Rs 377 per share.\n\n• Dividend Payout Value: Eligible equity holders will receive a gross distribution of Rs 377 on every share with a face value of Rs 10. The approved funds will be directly credited to the investor's linked bank account.\n• Purchase Deadline: The stock turns ex-dividend on April 28, 2023. Investors looking to capture this income stream must conclude their purchases before the ex-date.\n• Taxation Rules: All dividend receipts are treated as taxable income directly in the hands of the recipient. Investors falling into higher income tax brackets will incur obligations based on their applicable marginal rates.\n• Net Acquisition Impact: Receiving Rs 377 against the current trading price of Rs 5,750 effectively softens the entry cost. Capturing the projected Sharekhan target of Rs 6,200 would combine direct dividend yield with capital appreciation.",
  "whyItHappened": "Sanofi India announced a combined regular and special dividend distribution on the back of resilient operational earnings and comfortable liquidity reserves.\n\n• Robust Operational Trajectory: The company maintained strong financial execution across its core domestic and export drug portfolios over recent operating cycles. This underlying profitability supported the declaration of a 1940% final dividend component.\n• Special Dividend Distribution: In addition to the base dividend, the board approved an 1830% special payout. This supplemental corporate distribution reflects surplus capital reserves returned directly to the investor base.\n• Multinational Parent Strategy: The controlling group consisting of Sanofi and Hoechst GmbH holds a 60.4% equity stake in the company. Multinational pharmaceutical subsidiaries routinely use dividend mechanisms to deliver attractive capital yields from cash flows.",
  "questionsAndAnswers": [
    {
      "question": "What is the total dividend declared by Sanofi India?",
      "answer": "The company declared a total dividend of 3770%, which amounts to Rs 377 per share on a face value of Rs 10."
    },
    {
      "question": "What is the split between the final and special dividend?",
      "answer": "The distribution comprises a final dividend of 1940% and a special dividend of 1830%."
    },
    {
      "question": "What is the cutoff ex-dividend date to receive this payout?",
      "answer": "The shares will trade ex-dividend on April 28, 2023, requiring investors to purchase the stock prior to that date."
    },
    {
      "question": "What price target has Sharekhan established for the stock?",
      "answer": "Sharekhan issued a buy rating on Sanofi India with a price target of Rs 6,200."
    },
    {
      "question": "What are the 52-week high and low figures for Sanofi India shares?",
      "answer": "The stock recorded a 52-week high of Rs 7,938 and a 52-week low of Rs 5,240."
    },
    {
      "question": "How much stake do the promoter entities hold in Sanofi India?",
      "answer": "Sanofi and its wholly owned subsidiary Hoechst GmbH together hold a 60.4% stake in Sanofi India Limited."
    }
  ]
}